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esponsibility of Xi'aAbstract The stability of the drug actarit was studied under different stress conditions like hydrolysis (acid,
alkaline and neutral), oxidation, photolysis and thermal degradation as recommended by International Conference
on Harmonization (ICH) guidelines. Drug was found to be unstable in acidic, basic and photolytic conditions and
produced a common degradation product while oxidative stress condition produced three additional degradation
products. Drug was impassive to neutral hydrolysis, dry thermal and accelerated stability conditions. Degradation
products were identiﬁed, isolated and characterized by different spectroscopic analyses. Drug and the degradation
products were synthesized by a new route using green chemistry. The chromatographic separation of the drug
and its impurities was achieved in a phenomenex luna C18 column employing a step gradient elution by high
performance liquid chromatography coupled to photodiode array and mass spectrometry detectors (HPLC–PDA–
MS). A speciﬁc and sensitive stability-indicating assay method for the simultaneous determination of the drug
actarit, its process related impurities and degradation products was developed and validated.
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Actarit is an orally active immunomodulator used in the treatment
of rheumatoid arthritis. It suppresses secondary inﬂammation by
activation of Lyt-2þ cells and shows prophylactic and therapeutic
effects on secondary inﬂammation in adjuvant arthritis in rats
[1,2]. It prevents the progression of articular lesions [3] and also
curtails type II and type IV allergic reactions in mice [4–6].vier B.V. All rights reserved.
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methods have been reported in the literature for analysis of the
drug actarit; however, they are mainly related to its determination
in biological ﬂuids [7–9]. Estimation of actarit in pharmaceutical
formulation by HPLC was also reported [10] and the degradation
of actarit in alkaline and acidic solutions was evaluated. The
overall chemical stability of actarit was not sufﬁciently addressed
and this method cannot be considered as a method for indicating
stability. Photobiological properties of in vitro phototoxicological
assays and photodegradation products of actarit were studied [11].
The chemical stability of actarit with respect to other stress
conditions (oxidation, thermal) is presently unknown. An exhaus-
tive study on the stability of actarit is demanding as the current
International Conference on Harmonisation (ICH) guidelines
require that stability analysis should be done by using stability-
indicating assay methods (SIAM). After stress testing on the drug
under various conditions, including hydrolysis (at various pH),
oxidation, photolysis and thermal degradation and accelerated
stress conditions, SIAM should be developed and validated [12].
Forced degradation studies were carried out on the drug in order
to generate the potential degradation products under different
stress conditions as per ICH guidelines. Two potential degradation
products that were formed were isolated, characterized and
synthesized. The structural characterization of the degradation
product was determined using Fourier transform infrared spectro-
scopy (FTIR), liquid chromatography–tandem mass spectrometry
(LC–MS/MS), proton-nuclear magnetic resonance (1H NMR),
carbon-nuclear magnetic resonance (13C NMR), and hydrogen–
deuterium exchange nuclear magnetic resonance (D2O exchange
NMR). Degradation products which were formed in smaller
quantities in oxidative degradation were identiﬁed by high
performance liquid chromatography coupled to photodiode array
and mass spectrometry detectors (HPLC–PDA–MS).
Structural characterization of the major degradation products
enables one to establish the degradation pathway under which the
degradation products are formed. Synthesis of the drug assists in
identifying the process related impurities. This further helps with
the quantitative determination of the drug, in the presence of its
process related impurities and degradation products [13].
In the present work, intrinsic stability of the drug actarit was
found and a selective, precise and accurate HPLC–PDA–MSCH2COOH
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Fig. 1 Chemical structures for the drug actarit, its prmethod was developed for simultaneous determination of actarit,
its process related impurities and degradation products. Rate of
degradation of the drug was determined by performing hydrolysis
of the drug at different temperature conditions.2. Experimental
2.1. Reagents and chemicals
The drug actarit, its process related impurities (IMP) and degrada-
tion products (DP) were synthesized in the lab. Buffer salts and
glacial acetic acid were purchased from Merck, India. Highly
puriﬁed water for HPLC was obtained from Milli Q plus water
purifying system, Millipore. Methanol and acetonitrile of HPLC
grade were obtained from Fischer Scientiﬁc, India. Mobile phase
was vacuum ﬁltered through a 0.22 mm poly-tetraﬂuoroethylene
(PTFE) ﬁlter membrane and degassed using a sonicator to remove
the dissolved gases. Chemical structures for the drug, process
related impurities and degradation products are schematically
represented in Fig. 1. Chemical names for the drug, impurities
and degradation products are as follows: (A) Drug: p-acetylamino
phenyl acetic acid, (B) IMP-1/DP-I: p-amino phenyl acetic acid,
(C) IMP-2: p-amino acetophenone, (D) IMP-3: p-Acetylamino
acetophenone, (E) IMP-4/DP-II: p-acetylaminotoluene, (F) DP-III:
p-amino toluene, (G) DP-IV: 2-phenyl-1,2-oxaziridine, (H) IMP-5:
2-(4-aminophenyl)-1-morpholino ethane thione, and (I) IMP-6: N-
4-(2-morpholino-2-thioxoethyl)phenyl acetamide.
2.2. Instrumentation and chromatographic conditions
2.2.1. High pressure liquid chromatography (HPLC)
System conﬁguration of Shimadzu HPLC system consisted of two
LC-6AD pumps equipped with an SPDM20 (PDA) detector, and
was used throughout the analysis. Data analysis and interpretation
were carried out using Class VP software (6.14 SP1). The analyses
were carried out on a phenomenex luna C18 column
(250 mm 4.6 mm 10 mm). The measurements were carried
out at a wavelength of 244 nm for the analytes.
The mobile phase was prepared in two solvent reservoirs A and
B: Solvent reservoir A was a combination of aqueous ammoniumCOCH3
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A. Abiramasundari et al.376acetate buffer (pH 3.5; 10 mM, 450 mL), acetonitrile (25 mL) and
methanol (25 mL) and solvent reservoir B was a mixture of
methanol, acetonitrile and ammonium acetate buffer (pH 3.5,
10 mM) taken in an equal ratio. Flow rate used was 0.8 mL/min.
The HPLC step gradient method used the following run time
program: time (min)/solvent B concentration (%): 0.01–8.00/10,
8.01–15/20, 15.01–20.00/40, 20.01–26.00/60, 26.01–38.00/80,
38.01–40.00/60, 40.01–42.00/40, 42.01–43.00/20, and 43.01–
45.00/10.
Semipreparative HPLC system has the same conﬁguration as
that of analytical except for the column, ﬂow cell and ﬁxed loop
used. Semipreparative study [14,15] was performed with semi-
preparative phenomenex luna C18 column (250 mm 10
mm 10 mm), 0.5 mm path length ﬂow cell and ﬁxed loop
100 mL. Mobile phase used was the same. The ﬂow rate used
was 4.0 mL/min.
To ﬁnd the degradation products which were formed in smaller
quantities, the instrument used was HPLC–PDA–MS. The model
used was Thermo LCQ ﬂeet ion trap LC/MSn. Nitrogen was used
as the curtain gas and nebulizer gas. Collision induced dissociation
was achieved by helium as the collision gas. The mass spectra
were recorded in atmospheric pressure chemical ionization using
the positive mode of detection. Mobile phase used was the same as
that used in analytical chromatography. Stress samples of acid,
alkaline, photolytic and oxidative degradation mixtures were
subjected to HPLC–PDA–MS study to ﬁnd out the degradation
products which were formed in small quantities.
2.2.2. Accelerated conditions cabinet (ACC)
Humidity chamber (EIE Instruments Pvt. Ltd.) was employed to
carry out accelerated stability testing at ACC conditions. The
temperature was set at 4072 1C and the relative humidity at
7575%.
2.3. Chromatographic behavior of impurities and degradation
products
The behavior of the drug, impurities and degradation products
under different pH conditions was studied. Ammonium acetate
buffer (10 mM) was prepared in different pH values, ranging from
3.5 to 7 and the retentions of the impurities and degradation
products were studied.
2.4. Forced degradation conditions
The drug was accurately weighed to 10 mg, then dissolved in a
minimum amount of acetonitrile and made up to 10 mL by takingTable 1 Forced degradation condition applied for the drug.
Stress condition
Base hydrolysis (0.1M NaOH, 24h, 70 1C)
Acid hydrolysis (0.1M HCl, 24h, 70 1C)
Neutral hydrolysis (water, 14 days,70 1C)
Oxidative degradation (3% peroxide) (continuous stirring, RT, 14 days)
Photolytic degradation (photolytic chamber, 21 days, 25 1C)
Thermal degradation (dry heat,14 days, 70 1C)
Accelerated stability studies
Mass balance¼%Assay of drugþ %IMPþ%DP by peak area.
aMajor degradation product (DP) formed in the stress condition.either acid or base or water or 3% peroxide as per the requirement
of the stress study [16] so as to make the concentration of the drug
1 mg/mL. Forced degradation conditions employed are tabulated
in Table 1. In case of photolytic degradation, the drug was
subjected to UV and visible light radiations in a photolytic
chamber [17] (as per ICH guidelines). The drug sample was
exposed to light for an overall illumination of 1.2 million lx h and
an integrated near ultraviolet energy of 200 Wh/m2. Thermal
degradation studies were done by spreading a thin layer of the
drug in a petri dish and keeping the temperature maintained at
70 1C for a period of 14 days. Before HPLC analysis, acidic
samples were neutralized with 0.05 M base and then made up to
1 mL with the mobile phase; basic samples were neutralized by
taking 0.1 mL of the reaction mixture with 0.05 M HCl and then
made up to 1 mL with the mobile phase. In case of oxidative
studies, the reaction mixture was lyophilized and then 10 mg of the
compound was made up to 10 mL with acetonitrile. This solution
was diluted 10 times with the mobile phase and then injected.
Lyophilization procedure was done to prevent the injection of
peroxide into the column. The addition of the mobile phase to the
reaction mixture was to improve the peak shape in HPLC. The
chromatograms of the drug under all studied stress conditions are
represented in Fig. 2.
2.5. Rate of degradation kinetics
The drug was subjected to forced degradation studies using 0.1 M
HCl at three different temperature conditions (60 1C, 70 1C and
80 1C) for a time period of 125 h. Similar experiments were
carried out by changing the stress conditions to 0.1 M NaOH. Two
different concentrations (1000 mg/mL and 100 mg/mL) were used
to study the effect of concentration on the rate of degradation
kinetics. This was done systematically by taking 100 mL of the
solution from the reaction, neutralized and then made up to 1 mL
with the mobile phase. An aliquot of 20 mL was injected and then
analyzed. These experiments were conducted to investigate under
which conditions (acidic or basic) the degradation was greater and
also to ﬁnd out whether the degradation is dependent on the
concentration of the drug.
2.6. Stability of the drug
Stability of the drug was tested under different hydrolysis
conditions starting from pH 1 to 14. Drug solution of concentra-
tion 1 mg/mL was prepared in buffer solutions starting from pH 1
to 14 individually and the solution was continuously stirred. The
study was conducted for a period of 14 days at room temperature.DP-I DP-II % Assay Mass balance Remarks
14.08 – 85.62 99.7 DP-Ia
9.70 – 90.10 99.8 DP-Ia
– – 99.99 99.9 –
– 13.8 85.00 98.8 DP-IIa
1.2 – 98.5 99.7 DP-Ia
– – 99.98 99.98 –
– – 99.7 99.7 –
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2.7.1. Synthesis of DP-I (solvent free synthesis using
Willgerodt–Kindler reaction) and the drug
p-Amino acetophenone (IMP-2) was acetylated with acetyl chlor-
ide followed by the addition of a saturated solution of sodium
bicarbonate at lower temperature conditions. Once the reaction
was completed, the reaction mixture was extracted with ethyl
acetate. Ethyl acetate layer was separated, evaporated and the
product formed (IMP-3) was isolated and subjected to Willgerodt–
Kindler reaction. Willgerodt–Kindler reaction was carried out for
4 h at 120 1C in solvent free conditions [18]. The product
thiomorpholide (IMP-5) (200 mg) was taken and reﬂuxed with
10% alcoholic sodium hydroxide solution (25 mL). The progress
of the reaction was monitored through thin layer chromatographyCOCH
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Fig. 2 HPLC chromatograms of the drug under different forced
conditions: (A) drug; (B) acid stress conditions; (C) base stress
conditions; (D) neutral stress conditions; (E) photolytic stress condi-
tions; (F) thermal stress conditions; (G) accelerated stress conditions;
and (H) oxidative stress conditions.(TLC). Once the reaction was completed, the whole mixture was
neutralized with acid (30% HCl) and lyophilized. The ﬁnal
lyophilized product p-amino phenyl acetic acid [DP-I] was
recrystallized with methanol and water. In the above synthesis, it
is necessary to acetylate p-amino acetophenone to get the desired
product, thereby preventing the formation of N-oxide product
(Fig. 3).
The product p-amino phenyl acetic acid (300 mg, 20 mM) (DP-I)
was treated with acetyl chloride (350 mg, 24 mM) followed by the
addition of a saturated solution of sodium bicarbonate at lower
temperature conditions. Once the reaction was completed, the
reaction mixture was extracted with ethyl acetate. Ethyl acetate
layer was separated and evaporated to obtain the drug. The drug
actarit was recrystallized with methanol. The melting point of the
drug was found to be at 174 1C. The yield was found to be 70%.
The product was characterized using mass and NMR spectroscopy.
Instead of acetyl chloride, acetic anhydride can also be used.
In case of acetic anhydride, yield of the drug was greater than
80% [19].
2.7.2. Synthesis of DP-II
p-Toluidine (500 mg, 4.6 mM) was acetylated using acetyl chlor-
ide (540 mg, 6.9 mM) in the presence of saturated sodium
bicarbonate solution at lower temperature conditions to get the
product under solvent free conditions (Fig. 3).
2.8. Sample preparation for HPLC method validation
2.8.1. Preparation of standard solutions
Solution A: 10 mg of actarit reference standard was weighed
accurately and dissolved in a 10 mL volumetric ﬂask with
methanol. Solution B: A combined standard solution of accurately
weighed degradation products DP I/Imp-I (10 mg), Imp-2 (10 mg),
Imp-3 (10 mg), Imp-4 (10 mg)/DP II (10 mg), Imp-5 (10 mg), and
Imp-6 (10 mg) was prepared in a 10 mL volumetric ﬂask using
methanol.
2.8.2. Solution stability
Solution stability of actarit in the related substance method was
carried out by leaving analyte mixture solution (drug, degradation
products and impurities) in a tightly capped volumetric ﬂask at
room temperature for 2 days. Content uniformity of impurities
(IMP-1/DP-1, IMP-2, IMP-3, IMP-4/DP-2, IMP-5, and IMP-6)
was checked in the test solutions [20].N
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A. Abiramasundari et al.3783. Results and discussion
3.1. Optimization of mobile phase conditions
Method development of the drug in the preliminary studies
involved the use of methanol along with the buffer. During forced
degradation studies, chromatogram of the stressed mixtures
showed co-eluting peaks. The same problem was encountered
when acetonitrile was used alone with the buffer. The addition of
acetonitrile along with methanol led to the resolution of the
degradation products and the drug.
Analytes (process related impurities, degradation products, and
the drug) were found to be a mixture of acidic, basic and neutral
components. Hence, a modiﬁcation in pH altered the separation
selectivity for ionized or unionized solutes. Several trials were
made with the mobile phase by varying the pH of the buffer and
also by changing the proportions of the organic modiﬁer [21].
Ammonium acetate buffer:acetonitrile:methanol (90:5:5, v/v/v,
pump A) was used in combination with ammonium acetate buffer:
acetonitrile:methanol (50:50:50 in pump B). The method had a
total run time of 45 min using the step gradient method. In this
combination, buffer pH was checked with 3.5 and further trials
were done with pH values of 5–7. Better resolution was obtained
by adjusting the pH of the buffer to 5, which illustrates the
sensitivity of the polar compounds and the non-polar compounds
in a less acidic environment (Fig. 4). Peak shape and system
suitability parameters were improved as both the organic modiﬁersTime (min)
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Fig. 4 Chromatograms of the analytes (the drug, impurities and degradatio
pH 6.0, (D) pH 7.0, and (E) analytes at lower concentrations at pH 5.0.were used in the mobile phase. Peak purity for each peak was
found to be greater than 0.99. Mass spectra of the individual peaks
(the drug, process related impurities and degradation products)
which were obtained through HPLC–PDA–MS are shown in
Fig. 5.3.2. Mechanism
The drug follows an ionic pathway when it was subjected to
hydrolysis and a free radical degradation pathway when it was
undergoing degradation in the presence of peroxide (Fig. 6).
Acidic, basic and photolytic studies gave a common degradation
product DP-I.
Oxidative degradation studies gave a major degradation product
DP-II; DP-III and DP-IV were formed in smaller quantities.
Mechanism of the formation of the degradation products (DP-II,
DP-III and DP-IV) is schematically represented (Fig. 6). The
presence of carboxylic acid in the drug induces the removal of
carbon dioxide molecule through free radical pathway by initiating
the reaction of the drug with 3% peroxide [22]. Elimination of
ketene is observed, as it forms the amine (DP-III). DP-IV is
formed, as methane gets eliminated.
In acid degradation study, carbonyl carbon gets protonated and
becomes electrophilic. This leads to the attack of nucleophile
(water) and forms the tetrahedral intermediate. Nitrogen being a
base abstracts the proton from the positive oxonium ion and leavese (min)
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Fig. 5 Mass spectra of the analytes (the drug, impurities and degradation products) taken during the chromatographic run (pH 5.0) in HPLC–
PDA–MS: (A) Imp-1; (B) the drug; (C) Imp-2; (D) Imp-3; (E) Imp-4; (F) Imp-5; and (G) Imp-6.
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A. Abiramasundari et al.380as amine (DP-I, m/z 152). Carbocation formed is stabilized by the
oxonium ion which then loses a proton to give acid.
In base hydrolysis, hydroxide attacks the electropositive carbo-
nyl carbon, forming the tetrahedral intermediate and leads to the
elimination of amide anion. Amide anion abstracts the proton from
the acid and forms the neutral amine (DP-I, m/z 152) and
carboxylate anion.
In photolytic degradation, amide linkage breaks by free radical
mechanism and gives rise to the product DPI (m/z 152).
Fragmentation pattern for the drug, degradation products and
intermediate was self-explanatory (see Supplementary material).
3.3. Kinetic study
Kinetic studies of actarit (1000 mg/mL and 100 mg/mL) were
carried out for three different degradation studies such as acid,base conditions at three different temperature conditions (60 1C,
70 1C, and 80 1C) for a period of 125 h. The chromatograms
indicated that the peak area of the drug decreased with time,
revealing that the drug undergone degradation in acidic and basic
conditions.
The semilogarithmic plot of concentration of drug against time
for 0.1 M HCl/0.1 M NaOH degradation studies gave a straight line,
implicating that the degradation pathway has an apparent pseudo
ﬁrst order degradation behavior [23] (see Supplementary material).
It was observed that the rate constant of the reaction for both acid
and base hydrolysis increased with concentration of the acid, base
and also with the concentration of the drug. Increase in temperature
enhanced the rate of the reaction in alkaline conditions compared to
acidic conditions. The results are tabulated in Table 2. The
activation energy in basic and acidic conditions was found to be
11.86 J/mole and 64.45 J/mole, respectively.
3.4. Stability of the drug
The drug was found to be stable in neutral conditions. It was found
that stability of the drug increased as the pH increased from 1 to 6.
Degradation was found to increase, as the alkalinity increased.
3.5. Method validation
Gradient method which was developed to separate and quantify
the analytes (process related impurities, degradation products and
the drug) was checked for its efﬁcacy and was validated by the
following parameters.
3.5.1. System suitability
System suitability test was used to verify whether the system was
adequate for the analysis to be performed; it was an integral part of
chromatographic method development. System suitability para-
meters for the drug and impurities (Imp-1–6) were evaluated and
the results are shown in Table 3. Theoretical plates for the
impurities and the drug were greater than 2000 [24].
3.5.2. Speciﬁcity
The speciﬁcity of the developed method was determined by
spiking the drug with its six impurities (0.1% with respect to
actarit concentration). Speciﬁcity of the developed HPLC method
was established as the analytes were very well resolved from one
another (Fig. 3).
Upslope similarity, down-slope similarity and 3-point peak
purity for all the analytes were found to be greater than 0.99
and the peak purity index and single-point threshold for all the
analytes were found to be greater than 0.99. This conﬁrms that the
method has the ability to unambiguously determine the drug even
in the presence of process related impurities and degradation
products.
3.5.3. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
LOD and LOQ of all the impurities namely Imp-1 to -6 were
achieved. Precisions at the LOQ concentrations for all the six
impurities were below 2.0%. LODs of Imp-1, Imp-2, Imp-3, Imp-
4, Imp-5 and Imp-6 were 0.0797, 0.0384, 0.0746, 0.1119, 0.0566
and 0.0789 mg/mL, respectively. LOQs of Imp-1, Imp-2, Imp-3,
Imp-4, Imp-5 and Imp-6 were 0.2658, 0.1282, 0.2487, 0.3732,
0.1889, and 0.2024 mg/mL, respectively.
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Precision was determined in terms of intra-day repeatability and
inter-day reproducibility. The drug was spiked with 0.1% of the
impurities and the degradation products. Intra-day (repeatability)
and inter-day (reproducibility) data were determined for impurities
1–6 and the drug. The intermediate precision of the assay method
was also evaluated. The results are tabulated in Table 4.Table 2 Kinetics of the degradation of the drug in acid and
base mediated reactions.
Conditions Rate constants Half life
pH Temperature (1C) LCa HCb LCa HCb
Basic 60 0.01 0.03 46.22 21.00
70 0.05 0.11 13.86 6.07
80 0.06 0.13 10.82 5.13
Acidic 60 0.03 0.02 53.30 27.70
70 0.02 0.03 27.71 18.20
80 0.03 0.05 19.83 11.71
LCa: Low concentration of the drug.
HCb: High concentration of the drug.
Table 3 System suitability parameters for the drug, its
process related impurities and degradation products.
Compounds Capacity factor Resolution Tailing factor
DP-I/Imp-1 5.7 0.08 1.87
Imp-2 44.01 12.17 1.27
Imp-3 56.22 5.17 0.79
DP-II/Imp-4 60.40 3.36 1.12
Imp-5 64.22 3.85 1.35
Imp-6 63.92 3.91 1.58
Drug 8.13 5.23 1.39
Table 4 Precision data for the drug, its process related impurities an
Experiment Impurities
Conc.
(mg/mL)
RSD (%)
Imp-1 Imp-2 Imp-3 I
Repeatability 0.3 1.47 0.46 0.87 0
0.5 0.55 0.89 0.57 0
0.6 0.72 0.84 0.48 0
Reproducibility 0.3 0.75 0.69 0.92 0
0.5 0.45 0.27 0.84 0
0.6 0.77 0.49 0.94 0
Intermediate precision
Intra-day recovery 0.3 1.24 1.34 1.28 0
0.5 1.38 1.27 1.14 0
0.6 0.89 0.78 0.46 0
Inter-day recovery 0.3 1.26 0.88 1.31 1
0.5 0.57 0.81 0.54 0
0.6 0.72 0.69 0.85 03.5.5. Robustness
To determine the robustness, three parameters were varied: ﬂow
rate, pH and percent composition of the organic modiﬁer. The drug
was spiked with process related impurities and degradation
products and the resolution among the analytes was monitored.
The inﬂuence of pH of the mobile phase on the degradation
product and the impurities was also studied by analyzing the
standard mixture of analytes at three different pH values (Table 5).
The effect of mobile phase ﬂow rate on the drug and impurities
was evaluated by calculating the resolution factors and the results
are tabulated in Table 5.3.5.6. Linearity
Calibration solutions (drug) were prepared from stock at six
different concentration levels from 60% to 120% of the assay
analyte concentration (300, 350, 400, 450, 500, and 600 mg/mL).
Linearity test solution for the related substance method was
prepared by diluting the impurity stock solution to the required
concentrations. Six different concentration levels of the solutions
(impurities) were prepared in this range (LOQ–0.6 mg/mL).
Calibration studies for assay and purity method were carried out
for three consecutive days in the same concentration range. RSD
value for the slope and Y-intercept of the calibration curve was
calculated. Peak area under the curve (average peak area of the
triplicates) was plotted against the respective concentration level
(Table 6). Straight lines were obtained and the calibration equation
obtained from regression analysis was used to calculate the
corresponding predicted responses. Y-intercepts obtained for the
drug and other analytes were insigniﬁcant.3.5.7. Accuracy
The accuracy of the assay method was evaluated in triplicates at
three different concentration levels, i.e. 100, 400, and 600 mg/mL
in the bulk drug sample. The drug was spiked with 0.1%
impurities and degradation products, and the accuracy of the
impurities and degradation products was evaluated. Recovery
experiments were conducted to determine the accuracy of the
related substance method to quantify the impurities in bulk drug
samples. Percentage recoveries were calculated from the slope andd degradation products.
Drug
Conc.
(mg/mL)
RSD (%)
mp-4 Imp-5 Imp-6
.35 0.85 0.74 300 0.82
.84 0.72 1.38 500 0.45
.59 0.87 0.78 600 0.27
.39 1.30 0.96 300 0.37
.47 1.34 1.47 500 0.21
.84 0.89 0.79 600 0.71
.58 1.26 1.02 300 0.79
.72 1.24 1.43 500 0.68
.58 0.85 0.48 600 0.89
.24 1.10 1.02 300 0.58
.86 1.24 1.14 500 0.64
.91 0.79 0.69 600 0.74
Table 6 Linearity parameters for the drug, its process related impurities and degradation products.
Parameter Imp-1 Imp-2 Imp-3 Imp-4 Imp-5 Imp-6 Drug
Trend line
equation
y¼47,207x2254 y¼13,396xþ1020 y¼62,981x2518 y¼81,566x1462 y¼91,676x6563 y¼14,661x2272 y¼117,173x420,633
Linearity
range
(mg/mL)
0.2–0.6 0.1–0.6 0.2–0.6 0.3–0.6 0.1–0.6 0.2–0.6 100–600
Regression
coefﬁcient
0.9990 0.9991 0.9980 0.9995 0.9992 0.9980 0.9990
Slope 47,207 13,396 62,981 81,566 91,676 14,661 117,173
Intercept 2254 1020 2518 1462 6563 2272 420,633
P-value B 1.05e12 2.63e11 0.9049 0.9985 0.9973 0.029 2.2e16
P-value F 0.58 0.85 0.86 0.93 0.69 0.94 0.58
Chi square 4.69 2.62 2.54 1.88 3.86 1.65 13.23
Sensitivity 46,882 13,376 62,808 81,195 92,292 14,256 117,592
Table 5 Robustness data for the drug, its process related impurities and degradation product.
Parameters Value Resolution
Drug Imp-2 Imp-3 Imp-4 Imp-5 Imp-6
Flow rate (mL/min) 0.6 2.71 12.63 4.25 10.86 5.81 3.05
0.8 5.02 17.82 10.94 5.73 4.62 7.55
1.0 3.75 35.43 3.34 9.62 5.20 4.67
pH 4.9 7.42 21.83 10.01 1.98 4.74 3.73
5.0 8.99 13.28 15.64 2.01 4.99 6.98
5.1 8.12 12.12 16.64 1.32 4.22 4.59
Organic modiﬁer 10% 8.99 13.28 15.64 2.01 4.99 6.98
20% 3.18 20.24 13.26 1.20 1.54 4.32
A. Abiramasundari et al.382Y-intercept of the calibration curve developed for the drug.
Percentage recoveries for the drug and impurities were within
the range 96–102%.4. Conclusion
Synthesis of the drug was carried out taking into consideration the
green chemistry. The advantages of the synthetic methodology are
(i) simple method, (ii) good yield without using chromatographic
techniques, and (iii) environmentally friendly nature as it does not
produce toxic by-products. The intrinsic stability of the drug was
evaluated under different forced degradation conditions. The
developed stability-indicating assay method (SIAM) for the drug,
impurities and degradation products was validated as per ICH
guidelines. Degradation products that were found in smaller
quantities were identiﬁed using HPLC–PDA–MS.Acknowledgments
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